Alström Syndrome (AS) Alström Syndrome (AS) is an ultra-rare genetic disorder characterized by a spectrum of progressive symptoms, including vision and hearing loss, obesity, type 2 diabetes, cardio...
Professor Jiang Tao's Team from Beijing Tiantan Hospital Neurosurgery Leads the Establishment of China's First Advanced Innovative Treatment Clinic for Gliomas CureBreaking Through Treatment Dilemmas ...
Brain GliomaBrain glioma is one of the most common malignant tumors of the central nervous system. Despite numerous challenges in the treatment field, scientific advancements recently have brought new...
Advanced Pancreatic Cancer Treatment in China"We want to uncover the ultimate laws governing the true occurrence and development of pancreatic cancer and completely transform the treatment outcomes fo...
Phase III Trial: GC101 Gene Therapy for Type 2 Spinal Muscular Atrophy (SMA) ClinicalTrials.gov Identifier: NCT06971094Sponsor: GeneCradle Inc.Study Title: Safety and Efficacy Evaluation of GC101 Gen...
On May 15, 2025, the Food and Drug Administration sanctioned retifanlimab-dlwr (Zynyz, Incyte Corporation) in conjunction with carboplatin and paclitaxel for the initial treatment of people with inope...
On May 14, 2025, the Food and Drug Administration granted accelerated approval for telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.), a c-Met-targeted antibody and microtubule inhibitor conjugate, for...
On May 14, 2025, the Food and Drug Administration sanctioned belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients aged 12 and older diagnosed with locally advanced, unresectabl...
On May 8, 2025, the Food and Drug Administration approved the use of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adults with KRAS-mutated recurrent low-grade serous ovar...
On April 23, 2025, the Food and Drug Administration sanctioned penpulimab-kcqx (Akeso Biopharma Co., Ltd.) in conjunction with cisplatin or carboplatin and gemcitabine for the initial treatment of peo...